1. Market Research
  2. > Epistaxis - Pipeline Review, H1 2013

Epistaxis - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 20 pages

Epistaxis - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Epistaxis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Epistaxis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epistaxis. Epistaxis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Epistaxis.
- A review of the Epistaxis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Epistaxis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Epistaxis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Epistaxis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Epistaxis - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Epistaxis Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Epistaxis 6
Epistaxis Therapeutics under Investigation by Universities/Institutes 8
Mid Clinical Stage Products 9
Comparative Analysis 9
Epistaxis Therapeutics - Products under Investigation by Universities/Institutes 10
Epistaxis - Therapeutics Assessment 11
Assessment by Monotherapy Products 11
Assessment by Route of Administration 12
Assessment by Molecule Type 14
Drug Profiles 16
estriol - Drug Profile 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
bevacizumab - Drug Profile 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Epistaxis Therapeutics - Dormant Products 18
Appendix 19
Methodology 19
Coverage 19
Secondary Research 19
Primary Research 19
Expert Panel Validation 19
Contact Us 20
Disclaimer 20

List of Tables


Number of Products Under Development for Epistaxis, H1 2013 6
Products under Development for Epistaxis - Comparative Analysis, H1 2013 7
Number of Products under Investigation by Universities/Institutes, H1 2013 8
Comparative Analysis by Mid Clinical Stage Development, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Assessment by Monotherapy Products, H1 2013 11
Assessment by Stage and Route of Administration, H1 2013 13
Assessment by Stage and Molecule Type, H1 2013 15
Epistaxis Therapeutics - Dormant Products 18

List of Figures


Number of Products under Development for Epistaxis, H1 2013 6
Products under Development for Epistaxis - Comparative Analysis, H1 2013 7
Products under Investigation by Universities/Institutes, H1 2013 8
Mid Clinical Stage Products, H1 2013 9
Assessment by Monotherapy Products, H1 2013 11
Assessment by Route of Administration, H1 2013 12
Assessment by Stage and Route of Administration, H1 2013 13
Assessment by Molecule Type, H1 2013 14
Assessment by Stage and Molecule Type, H1 2013 15

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.